Recipients › New Jersey › Melinta Therapeutics, LLC
Recipient organisation · UEI H8K6F2A4KD49
Melinta Therapeutics, LLC
USAspending caveat. Figures are obligations reported by federal agencies to USAspending.gov, not payments. In USAspending's words: "An outlay occurs when federal money is actually paid out, not just promised to be paid ('obligated')." "Every agency has a Senior Accountable Official who must officially certify that the quarterly financial data submitted by their agency is accurate and complete." "If there are any discrepancies in procurement data, FPDS is the authoritative source." Contract data for the Department of Defense and the U.S. Army Corps of Engineers is published with a 90-day delay. Data loaded 30 Sep 2026. View the USAspending recipient profile.
USAspending records $48M in award obligations to Melinta Therapeutics, LLC (Parsippany, NJ) over the fiscal years it is listed for (2023, 2024, 2025).
Melinta Therapeutics, LLC ranks 221 of 734 listed organisations located in NJ by five-year obligations, and 9,985 of 30,989 nationally.
Its $1.0M-plus awards since FY2023 came from Department of Health and Human Services: 1 award worth $48M in total award value.
Its largest contract industry is NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)), where it ranks 24 of 174 organisations by the value of $1.0M-plus awards.
Obligations by fiscal year contracts vs assistance
| Fiscal year | All obligations | Contracts | Assistance | Change |
|---|---|---|---|---|
| FY2023 | $20,522,757 | $20,522,757 | $0 | — |
| FY2024 | $5,662,702 | $5,662,702 | $0 | -72% |
| FY2025 | $21,335,789 | $21,335,789 | $0 | +277% |
| FY2026 | under $1.0M | — | — | — |
| FY2027 to date | under $1.0M | — | — | — |
A fiscal year runs 1 October to 30 September. "Contracts" are procurement award types A–D; "assistance" is everything else (grants, direct payments, loan subsidy cost, insurance, other). The contracts column is listed only where contract obligations alone reached $1.0M; the assistance figure is the remainder and may therefore include up to $1.0M of contracts.
Compared with its state and the largest recipients five listed years
| Measure | This organisation | Largest in NJ | Largest nationally |
|---|---|---|---|
| Five-year obligations (listed years) | $48M | $79B | $416B |
| FY2026 obligations | under $1.0M | $22B | $118B |
| Contracts, five years | $48M | under $1.0M | $94B |
| Assistance, five years | $0 | $79B | $416B |
| Rank by five-year obligations | 9,985 of 30,989 | 1 of 734 in NJ | 1 |
Largest in state: Human Services, New Jersey Department of. Largest nationally: Health Care Services, California Department of. Rankings count organisations located in the state, by the sum of their listed fiscal years.
Awarding agencies $1.0M+ awards since FY2023
| # | Agency | Awards | Award value | Share |
|---|---|---|---|---|
| 1 | Department of Health and Human Services | 1 | $48M | 100% |
Contract industries NAICS
Rank within NAICS 541714: 24 of 174 organisations by $1.0M+ award value; see Research and Development in Biotechnology (except Nanobiotechnology).
Places of performance $1.0M+ awards
Counties: District of Columbia, DC $48M
Largest awards begun since FY2023
| Awarding agency | Type | Industry or program | Award value | Begun | Place | Record |
|---|---|---|---|---|---|---|
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDefinitive Contract | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $48M | 6 Jul 2023 | DC | USAspending |
Award value is the amount obligated to the award to date as USAspending reports it. Descriptions below are USAspending's text, unedited and truncated; those that appear to name a person are withheld.
- $48M, Department of Health and Human Services, 6 Jul 2023: ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGAN
Questions and answers
How much federal money does Melinta Therapeutics, LLC receive?
$48M in award obligations over the fiscal years it is listed for (FY2023: $21M; FY2024: $5.7M; FY2025: $21M). Years not listed were under the $1.0M floor. Obligations are binding commitments, not payments made.
Which agencies award to Melinta Therapeutics, LLC?
By the value of $1.0M-plus awards begun since FY2023: Department of Health and Human Services ($48M).
What is the money for?
Contracts are classified under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology).
Where is the work performed?
Primary places of performance for its larger awards: DC ($48M).
Is Melinta Therapeutics, LLC a large federal recipient?
It ranks 9,985 of 30,989 organisations on this site by five-year obligations and 221 of 734 located in NJ. The site covers organisations with at least $1.0M in a fiscal year; individuals are excluded.
Where does this data come from?
USAspending.gov (U.S. Treasury), award transactions as loaded on 30 Sep 2026; fiscal-year totals via the spending-by-category endpoint and award lists via the award search endpoint. The USAspending recipient profile is the authoritative record.
Provenance
Source: USAspending.gov API v2 (U.S. Department of the Treasury, Bureau of the Fiscal Service), CC0. Fiscal-year obligations from the spending-by-category recipient ranking by recipient state (listing floor $1.0M per year); awards from the award search endpoint (new awards of $1.0M or more by base obligation date); parent and business categories from the recipient profile where fetched. Closed fiscal years are snapshots taken after year end; FY2027 is refreshed on each build. Data loaded by USAspending on 30 Sep 2026. Individuals and sole proprietors are excluded at ingest. Errors in processing are corrected at the next build; see corrections and the methodology.